Chardan raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $9 and keeps a Buy rating on the shares. The company reported that it has commenced site activation activities for the pivotal Part B REVEAL trial of TSHA-102 for Rett syndrome, and expects to report additional supplemental data from Part A of the trial in Q4, the analyst tells investors in a research note. The company also expects its cash position to support a runway into 2028 vs. into Q4 from February 2025 guidance, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Taysha Gene Therapies: Positive Outlook with Pivotal Study and Strong Financial Health Justifies Buy Rating
- Taysha Gene Therapies reports Q2 EPS (9c), consensus (8c)
- TSHA Earnings this Week: How Will it Perform?
- Vinay Prasad returns to FDA as head of CBER
- Taysha Gene Therapies initiated with a Buy at BofA